共 50 条
- [21] ISEL: a Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimensLUNG CANCER, 2005, 49 : S4 - S4Thatcher, NChang, AParikh, PPemberton, KArcher, V
- [22] A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal CancerCLINICAL CANCER RESEARCH, 2018, 24 (02) : 316 - 325Grothey, AxelStrosberg, Jonathan R.Renfro, Lindsay A.Hurwitz, Herbert I.Marshall, John L.Safran, HowardGuarino, Michael J.Kim, George P.Hecht, J. R.Weil, Susan C.Heyburn, JohnWang, WenquanSchweizer, CharlesO'Shannessy, Daniel J.Diaz, Luis Alberto, Jr.
- [23] A double-blinded, placebo-controlled, randomized, phase III study of axitinib (AG-013736; A) plus gemcitabine (G) vs. G plus placebo (P) in advanced pancreatic cancer (PC) patients (pts)EJC SUPPLEMENTS, 2009, 7 (02): : 361 - 362Kindler, H. L.Ioka, T.Richel, D. J.Bennouna, J.Letourneau, R.Okusaka, T.Bycott, P.Ricart, A. D.Kim, S.Van Cutsem, E.
- [24] TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Ilson, David H.Tabernero, JosepShitara, KoheiWinkler, RobertNasermoaddeli, AliDing, CliffDoi, Toshihiko
- [25] A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndromeAMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (09) : E156 - E162Garcia-Manero, GuillermoGartenberg, GarySteensma, David P.Schipperus, Martin R.Breems, Dimitri A.de Paz, RaquelValcarcel, DavidKranenburg, BritteReddy, ManjulaKomrokji, Rami S.
- [26] A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM)ANNALS OF ONCOLOGY, 2006, 17 : 214 - 214Jassem, JacekRamlau, RodrygSantoro, ArmandoSchuette, WolfgangChemaissani, AssadHong, ShengyanBlatter, JohannesAdachi, SusumuHanauske, Axel-RManegold, Christian
- [27] Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S340 - S340Goss, GlenwoodFerry, DavidLaurie, ScottWierzbicki, RafalThompson, JoyceBiesma, B.Duffield, EmmaGhiorghiu, SerbanZarenda, MarcArmour, Alison
- [28] Vinorelbine plus best supportive care (BSC) vs BSC in the treatment of advanced non small cell lung cancer (NSCLC) elderly patients (pts). Results of a phase III randomized trialANNALS OF ONCOLOGY, 1998, 9 : 62 - 62Clerici, MFrontini, LIanniello, GPMaiorino, LPiantedosi, FVCigolari, SManzione, LFailla, GZuccarino, LPedicini, TVinante, OCastiglione, FBearz, ATonato, MRossi, AMonfardini, SGallo, CPerrone, FGridelli, C
- [29] Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 studyJOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)Lenz, Heinz-JosefTabernero, JosepYoshino, TakayukiLonardi, SaraFalcone, AlfredoMiron, Maria Luisa LimonSaunders, Mark P.Sobrero, Alberto F.Park, Young SukMonteagudo, Reyes FerreiroHong, Yong SangTomasek, JiriTaniguchi, HiroyaCiardiello, FortunatoSassi, MounaPeil, BarbaraHastedt, ClaudiaStudeny, MatusVan Cutsem, Eric